BCL2 and glioma: A better understanding of the exact mechanisms of the “switching” processes between apoptosis and autophagy through PI3K and Raf inhibitor usage in the context of the Bcl-2:beclin-1 complex formation opens up new perspectives in the fight against gliomas, both in the context of designing new therapies and exploring their resistance to elimination through programmed death.